Yen-Chuan Ou

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I. Rini, Bernard Escudier, Piotr Tomczak et al. · The Lancet · 2011 · 1.8K citations

Medicine, Oncology, Pharmacology +8

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

M. Dror Michaelson, Stéphane Oudard, Yen-Chuan Ou et al. · Journal of Clinical Oncology · 2013 · 190 citations

Medicine, Oncology, Pharmacology +14

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Medicine, Oncology, Pharmacology +16

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

William Oh, David F. McDermott, Camillo Porta et al. · International Journal of Oncology · 2013 · 36 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Intracellular glutathione content of urothelial cancer in correlation to chemotherapy response

Chi‐Rei Yang, Chi‐Rei Yang, Yen-Chuan Ou et al. · Cancer Letters · 1997 · 27 citations

Medicine, Cancer Biology, Oncology +12